Jaime Rosenberg


Panel Offers Consensus Recommendations for MRD Assessment in CLL

November 24, 2021

The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed duration of treatment feasible goals.

Researchers Identify Novel Biomarker, Therapeutic Target for Polycythemia Vera

November 24, 2021

The data set included 177 samples from polycythemia vera, essential thrombocytopenia, primary myelofibrosis, and healthy donors, from which the researchers found that MAPK14 was overexpressed in PV samples and was associated with more symptoms and worse outcomes.

GVHD Insights Point to Importance of Immunometabolism to Control Disease

November 13, 2021

According to the study authors, a growing number of findings from preclinical studies have suggested a focus on immunometabolism to modulate alloreactive donor T cell responses to control graft-versus-host disease (GVHD) and promote graft-versus-tumor effect.

New Research Underscores Need for More Diversity in Precision Oncology Studies

November 11, 2021

Across all studies included, observed-to-expected ratios showed that White and Asian patients were overrepresented while Black patients, Hispanic patients, and American Indian/Alaskan Native patients were underrepresented.

Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL

September 29, 2021

These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.